GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on August 26, 2025. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC. As of July 1, 2024, the Company operates as a fully remote entity without a principal executive office.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the execution of Amendment No. 3 to the Employment Agreement with Michael Breen, Executive Chairman and Chief Executive Officer. Key terms include:
- Effective Date: April 29, 2025.
- Term Renewal: Mr. Breen's position as CEO was renewed for a two-year period from the Effective Date.
- Automatic Renewal: Upon expiration, the employment term automatically renews for additional two-year periods unless either party provides at least 90 days' written notice of non-renewal.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure regarding the executive agreement.
Investor Verification Checklist
- Review the full text of Amendment No. 3 (Exhibit 10.1) to verify specific compensation details, severance provisions, and performance conditions not summarized in the 8-K.
- Confirm the Company's current cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Verify the status of the Company's clinical pipeline and regulatory milestones, as the filing does not address operational progress.